What's New

Last Posted: Jun 12, 2019

• Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
  Couraud Sébastien et al. European journal of cancer (Oxford, England : 1990) 2019 Jun 11686-97
• Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
  Huang Ruofan et al. Targeted oncology 2019 Jun
• Mutational profile of non-small cell lung cancer patients: Use of next-generation sequencing.
  Reis D et al. Pulmonology 2019 Jun
• Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates.
  Boccellino Mariarosaria et al. Journal of cellular physiology 2019 Jun
• The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.
  Lin Victor T G et al. Journal of the National Cancer Institute 2019 Jun
• Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer.
  Griffith Sandra D et al. Advances in therapy 2019 May
• Assessment of tumor mutation burden calculation from gene panel sequencing data.
  Xu Zhenwu et al. OncoTargets and therapy 2019 123401-3409
• Development of predictive models to identify advanced-stage cancer patients in a US healthcare claims database.
  Esposito Daina B et al. Cancer epidemiology 2019 May 6130-37
• Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition.
  Oellerich Michael et al. Clinica chimica acta; international journal of clinical chemistry 2019 May
• Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
  Wang Yubo et al. Lung cancer (Amsterdam, Netherlands) 2018 118105-110
• [The national Network Genomic Medicine (nNGM) : Model for innovative diagnostics and therapy of lung cancer within a public healthcare system].
  Büttner R et al. Der Pathologe 2019 May
• A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
  Zuo Shuguang et al. Journal of translational medicine 2019 May 17(1) 152
• Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer.
  Fang Wenfeng et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 May
• Diagnostic Accuracy of FOBT and Colorectal Cancer Genetic Testing: A Systematic Review & Meta-Analysis.
  Ramdzan Abdul Rahman et al. Annals of global health 2019 May 85(1)
• EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.
  Hastings K et al. Annals of oncology : official journal of the European Society for Medical Oncology 2019 May